Clover Biopharmaceuticals, Inc.
B-A10 Room No.1, Mansion
Chengdu Hi-tech Zone Hi-tech Incubation Park
Tianhe Incubator, Nan Yan Xian Tian Fu Avenue
Chengdu
610041
China
Tel: 028-85336966
Fax: 028-85336933
Website: http://www.cloverbiopharma.com/
Email: jiang.pu@cloverbiopharma.com
About Clover Biopharmaceuticals, Inc.
Clover Biopharmaceuticals is a global, clinical-stage, research-based biotechnology company focused on discovering, developing and commercializing transformative biologic therapies, with a focus on oncology and autoimmune diseases. Clover is utilizing its proprietary Trimer-Tag technology platform to develop novel biologics targeting trimerization-dependent pathways. Additionally, Clover is leveraging its in-house cGMP biomanufacturing capabilities to develop select biosimilars.
LEADERSHIP:
Founders: Peng Liang, Xiaodong Wang and Jianwei Zhu
CSO: Joshua Liang
COO: Zheng Ping
CIO: Pu Jiang
CLINICAL TRIAL:
95 articles about Clover Biopharmaceuticals, Inc.
-
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for March 2, 2021.
-
Money on the Move: February 17-23
2/24/2021
Life sciences companies across the globe are raking in investment dollars to advance drug programs. -
Clover Biopharmaceuticals Raises $230 Million in Oversubscribed Series C Financing
2/23/2021
The proceeds will support the continued development and expansion of Clover's pipeline of protein-based vaccines and biologic cancer therapies
-
Chinese fusion protein company Clover Biopharmaceuticals raised a $230 million series C round co-led by GL Ventures and Temasek, which will push its COVID-19 vaccine into Phase II/III testing and production planning.
-
It was a busy week for clinical trial updates. Here’s a look.
-
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for February 2, 2021.
-
Clover Biopharmaceuticals Announces Publication of Phase 1 Clinical Trial Data for its Adjuvanted COVID-19 Vaccine Candidates in The Lancet
2/1/2021
Clover plans to initiate a global phase 2/3 trial in the first half of 2021 with an interim analysis for vaccine efficacy potentially in the middle of 2021
-
Clover and Dynavax Announce Planned Global Phase 2/3 Efficacy Trial of Adjuvanted COVID-19 Vaccine Candidate - Feb 01, 2021
2/1/2021
Clover plans to initiate a global Phase 2/3 efficacy trial of its protein-based S-Trimer COVID-19 vaccine candidate adjuvanted with Dynavax's CpG 1018 plus alum in the first half of 2021 with an interim analysis for vaccine efficacy potentially in the middle of 2021.
-
Clover and Dynavax Announce Planned Global Phase 2/3 Efficacy Trial of Adjuvanted COVID-19 Vaccine Candidate
2/1/2021
The Coalition for Epidemic Preparedness Innovations (CEPI) continues to support Clover's COVID-19 vaccine candidate and will fund its development through licensure.
-
China’s Clover Biopharmaceuticals is spurning GlaxoSmithKline’s adjuvant vaccine technology in favor of one created by California-based Dynavax Technologies.
-
Clover Biopharmaceuticals Announces Positive Phase 1 Data for its Adjuvanted S-Trimer COVID-19 Vaccine Candidates
12/4/2020
Clover’s protein-based COVID-19 vaccine candidates adjuvanted with either GSK’s pandemic adjuvant system or Dynavax’s CpG 1018 plus alum induced strong neutralizing immune responses in 150 adult and elderly subjects from the Phase 1 clinical study.
-
Cytiva supports Clover Biopharmaceuticals to scale up the output of its vaccine candidate
11/16/2020
Cytiva provides FlexFactory™ bioprocessing upstream and downstream solutions for Clover to accelerate GMP facility development and shorten time to market
-
BioSpace Movers & Shakers, Oct. 2
10/2/2020
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers. -
Clover Biopharmaceuticals Announces Formation of a Global Scientific Advisory Board for its COVID-19 Vaccine Program
9/25/2020
Clover Biopharmaceuticals, a global clinical-stage biotechnology company focused on discovering and developing transformative biologic therapies and vaccines, today announced the formation of its Scientific Advisory Board (SAB) comprised of internationally-renowned experts in the vaccine industry, public health and policy making
-
Clover Biopharmaceuticals Announces Positive Preclinical Data and Updates on Phase 1 Study for its Adjuvanted S-Trimer COVID-19 Vaccine Candidate
9/25/2020
Preclinical data show Clover’s protein-based adjuvanted COVID-19 vaccine candidate, S-Trimer, induces a strong neutralizing immune response in animalsand protects nonhuman primates from SARS-CoV-2 challenge
-
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for June 22, 2020.
-
Dynavax and Clover Biopharmaceuticals Announce Research Collaboration to Evaluate Coronavirus (COVID-19) Vaccine Candidate with CpG 1018 Adjuvant
3/24/2020
Dynavax is providing CpG 1018, the adjuvant contained in U.S. FDA-approved HEPLISAV-B vaccine, to support the rapid development of Clover’s COVID-19 vaccine Clover advancing evaluation of its protein-based coronavirus vaccine candidate (COVID-19 S-Trimer) EMERYVILLE, Calif. and CHENGDU, China, March 24, 2020 (GLOBE NEWSWIRE) -- Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, and Clover Biopharmaceut
-
A summary of daily biopharma industry news. Please check out stories that are trending on March 24, 2020.
-
As the coronavirus outbreak that causes COVID-19 escalates, biopharma companies and government agents are working quickly to develop and test a vaccine, although most estimates are it will take 12 to 18 months before it could get to market.
-
Clover and GSK Announce Research Collaboration to Evaluate Coronavirus (COVID-19) Vaccine Candidate with Pandemic Adjuvant System
2/24/2020
Clover Biopharmaceuticals, a China based global clinical-stage biotechnology company focused on developing novel and transformative biologic therapies, announced that it has entered into a research collaboration with GSK for its protein-based coronavirus vaccine candidate.